This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Dec;3(12):931.

doi: 10.1016/S2213-8587(15)00439-8.

Preventing cardiovascular events with empagliflozin: at what cost?

Huseyin Naci¹, Sanjay Basu², John S Yudkin³

Affiliations

Affiliations

¹ LSE Health, Department of Social Policy, London School of Economics and Political Science, London WC2A 2AE, UK. Electronic address: h.naci@lse.ac.uk.
² Prevention Research Center, Centers for Health Policy, Primary Care, and Outcomes Research, Center on Poverty and Inequality, and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
³ Division of Medicine, University College London, London, UK.

PMID: 26590682
DOI: 10.1016/S2213-8587(15)00439-8

Comment

Preventing cardiovascular events with empagliflozin: at what cost?

Huseyin Naci et al. Lancet Diabetes Endocrinol. 2015 Dec.

. 2015 Dec;3(12):931.

doi: 10.1016/S2213-8587(15)00439-8.

Authors

Huseyin Naci¹, Sanjay Basu², John S Yudkin³

Affiliations

¹ LSE Health, Department of Social Policy, London School of Economics and Political Science, London WC2A 2AE, UK. Electronic address: h.naci@lse.ac.uk.
² Prevention Research Center, Centers for Health Policy, Primary Care, and Outcomes Research, Center on Poverty and Inequality, and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
³ Division of Medicine, University College London, London, UK.

PMID: 26590682
DOI: 10.1016/S2213-8587(15)00439-8

No abstract available

PubMed Disclaimer

Comment on

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Zinman B, et al. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. N Engl J Med. 2015. PMID: 26378978 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information